Ignyta

Biotechnology company catalyzing personalized medicine in autoimmune diseases.

Launch date

2011

Market cap

Enterprise valuation

San Diego California (HQ)

Revenues, earnings & profits over time

EUR	2015	2016
R&D budget	68.0m	73.0m

Source: Dealroom estimates

Date	Investors	Amount	Round
Dec 2012	Silicon Valley Bank City Hill Ventures Colt Ventures	$5.5m	Series B
Feb 2013	N/A	$1.0m	Debt
Dec 2013	N/A	$54.0m	Early VC
Jan 2014	Silicon Valley Bank	$10.0m	Debt
Mar 2014	N/A	$55.2m	IPO
Oct 2014	Silicon Valley Bank	$31.0m	Post IPO Debt
Mar 2015	Teva	$42.0m	Post IPO Debt
Nov 2015	N/A	$30.0m	Post IPO Equity
Jun 2016	Silicon Valley Bank Oxford Finance	$42.0m	Post IPO Debt
Oct 2017	N/A	$160m	Post IPO Equity
Dec 2017	Roche	$1.7b	Acquisition
Total Funding		€54.1m

Tech stackLearn more about the technologies and tools that this company uses.

Financials